In summary, our results showed that the CDK7-p38α-MYC axis-dependent regulation of PD-L1 plays a critical role in NSCLC and thus provided a promising strategy for applying THZ1 for boosting antitumor immunity of antiPD-1 therapy (Fig. 6l). This evidence concerns the gene MYC and non-small cell lung carcinoma.